Total Funding
90
53
Total FundingSeries A raised
Growth Score
-1 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
17088
Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies to treat neurological diseases.
- Alpna Seth: CEO, President and Board Member
- Sanjay Keswani: Board Of DirectorsPast Role: Annexon Biosciences, EVP & CMO
About the Company
Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies to treat neurological diseases. Nura Bio’s drug candidate, NB-4746, is designed to inhibit the SARM1 protein, which plays a significant role in axon degeneration. This drug has shown promise in preclinical studies for preventing nerve damage and
is currently advancing toward phase 1b/2 clinical trials in 2025. The company has raised $140 million in financing to support this and other neuroprotective drug programs.
Women Led
